RNAC vs. RNA, GPCR, ACAD, TGTX, RYTM, BHC, JANX, INDV, DCPH, and MRVI
Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Avidity Biosciences (RNA), Structure Therapeutics (GPCR), ACADIA Pharmaceuticals (ACAD), TG Therapeutics (TGTX), Rhythm Pharmaceuticals (RYTM), Bausch Health Companies (BHC), Janux Therapeutics (JANX), Indivior (INDV), Deciphera Pharmaceuticals (DCPH), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.
Avidity Biosciences (NASDAQ:RNA) and Cartesian Therapeutics (NASDAQ:RNAC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
Avidity Biosciences received 127 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cartesian Therapeutics an outperform vote while only 64.79% of users gave Avidity Biosciences an outperform vote.
87.0% of Cartesian Therapeutics shares are held by institutional investors. 3.7% of Avidity Biosciences shares are held by company insiders. Comparatively, 61.1% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Cartesian Therapeutics has a net margin of -983.93% compared to Cartesian Therapeutics' net margin of -2,103.78%. Cartesian Therapeutics' return on equity of -37.98% beat Avidity Biosciences' return on equity.
Avidity Biosciences has higher earnings, but lower revenue than Cartesian Therapeutics.
Avidity Biosciences has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
In the previous week, Avidity Biosciences had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 11 mentions for Avidity Biosciences and 7 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.71 beat Avidity Biosciences' score of 0.42 indicating that Avidity Biosciences is being referred to more favorably in the media.
Avidity Biosciences currently has a consensus price target of $41.33, suggesting a potential upside of 56.21%. Cartesian Therapeutics has a consensus price target of $45.00, suggesting a potential upside of 27.91%. Given Cartesian Therapeutics' higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Cartesian Therapeutics.
Summary
Avidity Biosciences beats Cartesian Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Cartesian Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cartesian Therapeutics Competitors List
Related Companies and Tools
